Explore
Validate
LearnMN1050
antibody from Invitrogen Antibodies
Targeting: MAPT
DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [164]
- Comments [0]
- Validations
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MN1050 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-Tau (Thr181) Monoclonal Antibody (AT270)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MN1050 recognizes PHF-Tau, tangles and neurofilaments. Cross reacts weakly with normal Tau. Does not cross react with recombinant unphosphorylated Tau. The epitope of this antibody is the phosphorylated Thr181 residue (numbering according to human Tau40). MN1050 detects PHF-tau (Thr181) which has a predicted molecular weight of approximately 79 kDa. Purity is >95% as determined by SDS-PAGE.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- AT270
- Vial size
- 100 µg
- Concentration
- 0.2 mg/mL
- Storage
- -20° C, Avoid Freeze/Thaw Cycles
Submitted references Dysfunction of the retromer complex system contributes to amyloid and tau pathology in a stem cell model of Down syndrome.
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein.
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease.
UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation.
PKR kinase directly regulates tau expression and Alzheimer's disease-related tau phosphorylation.
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Neurofilament light chain in the vitreous humor of the eye.
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.
Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification.
Hibernation Impairs Odor Discrimination - Implications for Alzheimer's Disease.
Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy.
Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease.
MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain.
Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.
Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports.
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.
The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology.
Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.
Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer's disease.
A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo.
NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency.
Phosphorylation of nuclear Tau is modulated by distinct cellular pathways.
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.
Tau secretion is correlated to an increase of Golgi dynamics.
Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects.
Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.
Rab7A regulates tau secretion.
Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology.
A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.
12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice.
Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer's disease.
Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: role of autophagy.
Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model.
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype.
Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction.
miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain.
Dendritic Spine Loss and Chronic White Matter Inflammation in a Mouse Model of Highly Repetitive Head Trauma.
Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner.
The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.
Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models.
Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model.
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy.
HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.
Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Modulation of AD neuropathology and memory impairments by the isoprostane F2α is mediated by the thromboxane receptor.
Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase.
Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production.
Site-specific phosphorylation of Tau protein is associated with deacetylation of microtubules in mouse spermatogenic cells during meiosis.
Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.
Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice.
Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes.
Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.
Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition.
α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles.
Visualizing the microtubule-associated protein tau in the nucleus.
Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.
Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.
SorLA deficiency dissects amyloid pathology from tau and cholinergic neurodegeneration in a mouse model of Alzheimer's disease.
Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.
Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.
Clinical correlates in an experimental model of repetitive mild brain injury.
Ankyrin-B structurally defines terminal microdomains of peripheral somatosensory axons.
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.
Sex-dependent alterations in social behaviour and cortical synaptic activity coincide at different ages in a model of Alzheimer's disease.
Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology.
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice.
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.
Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease.
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors.
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway.
Hippocampal BDNF expression in a tau transgenic mouse model.
Hippocampal BDNF expression in a tau transgenic mouse model.
Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates.
Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models.
Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols.
Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice.
Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies.
Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B.
Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease.
Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia.
Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice.
Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease.
Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation.
A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.
The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.
Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant.
A peculiar constellation of tau pathology defines a subset of dementia in the elderly.
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.
The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease.
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation.
Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice.
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.
Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.
Oligemic hypoperfusion differentially affects tau and amyloid-{beta}.
Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo.
Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease.
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy.
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.
Anesthesia induces phosphorylation of tau.
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains.
AnkyrinG is required to maintain axo-dendritic polarity in vivo.
Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy.
Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly.
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease.
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.
A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau.
Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model.
Development of a non invasive NGF-based therapy for Alzheimer's disease.
Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice.
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
Oxidative stress mediates tau-induced neurodegeneration in Drosophila.
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.
Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices.
The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity.
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.
FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation.
Lithium can relieve translational repression of TOP mRNAs elicited by various blocks along the cell cycle in a glycogen synthase kinase-3- and S6-kinase-independent manner.
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules.
Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model.
Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ.
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats.
Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats.
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.
Curtis ME, Smith T, Blass BE, Praticò D
Alzheimer's & dementia (New York, N. Y.) 2022;8(1):e12334
Alzheimer's & dementia (New York, N. Y.) 2022;8(1):e12334
Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease.
Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS, Mathotaarachchi S, Therriault J, Savard M, Chamoun M, Stoops E, Francois C, Vanmechelen E, Gauthier S, Zimmer ER, Zetterberg H, Blennow K, Rosa-Neto P
EBioMedicine 2022 Feb;76:103836
EBioMedicine 2022 Feb;76:103836
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
Pérez MJ, Ivanyuk D, Panagiotakopoulou V, Di Napoli G, Kalb S, Brunetti D, Al-Shaana R, Kaeser SA, Fraschka SA, Jucker M, Zeviani M, Viscomi C, Deleidi M
Molecular psychiatry 2021 Oct;26(10):5733-5750
Molecular psychiatry 2021 Oct;26(10):5733-5750
Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein.
Lin G, Zhu F, Kanaan NM, Asano R, Shirafuji N, Sasaki H, Yamaguchi T, Enomoto S, Endo Y, Ueno A, Ikawa M, Hayashi K, Yamamura O, Yen SH, Nakamoto Y, Hamano T
International journal of molecular sciences 2021 Nov 8;22(21)
International journal of molecular sciences 2021 Nov 8;22(21)
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C, Lewczuk P, Kornhuber J, Richiardi J, Maréchal B, Karikari TK, Blennow K, Zetterberg H, Popp J
Alzheimer's research & therapy 2021 Mar 25;13(1):65
Alzheimer's research & therapy 2021 Mar 25;13(1):65
Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease.
McMillan PJ, Strovas TJ, Baum M, Mitchell BK, Eck RJ, Hendricks N, Wheeler JM, Latimer CS, Keene CD, Kraemer BC
Acta neuropathologica communications 2021 Jun 29;9(1):117
Acta neuropathologica communications 2021 Jun 29;9(1):117
UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation.
Subramanian M, Hyeon SJ, Das T, Suh YS, Kim YK, Lee JS, Song EJ, Ryu H, Yu K
Nature communications 2021 Jun 2;12(1):3291
Nature communications 2021 Jun 2;12(1):3291
PKR kinase directly regulates tau expression and Alzheimer's disease-related tau phosphorylation.
Reimer L, Betzer C, Kofoed RH, Volbracht C, Fog K, Kurhade C, Nilsson E, Överby AK, Jensen PH
Brain pathology (Zurich, Switzerland) 2021 Jan;31(1):103-119
Brain pathology (Zurich, Switzerland) 2021 Jan;31(1):103-119
Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, Suárez-Calvet M, Zetterberg H, Blennow K, Schöll M, Alzheimer’s Disease Neuroimaging Initiative
Brain : a journal of neurology 2021 Feb 12;144(1):325-339
Brain : a journal of neurology 2021 Feb 12;144(1):325-339
Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein.
Martinez-Valbuena I, Valenti-Azcarate R, Amat-Villegas I, Marcilla I, Marti-Andres G, Caballero MC, Riverol M, Tuñon MT, Fraser PE, Luquin MR
Acta neuropathologica communications 2021 Apr 8;9(1):64
Acta neuropathologica communications 2021 Apr 8;9(1):64
Screening of tau protein kinase inhibitors in a tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization.
Yadikar H, Torres I, Aiello G, Kurup M, Yang Z, Lin F, Kobeissy F, Yost R, Wang KK
PloS one 2020;15(7):e0224952
PloS one 2020;15(7):e0224952
Neurofilament light chain in the vitreous humor of the eye.
Subramanian ML, Vig V, Chung J, Fiorello MG, Xia W, Zetterberg H, Blennow K, Zetterberg M, Shareef F, Siegel NH, Ness S, Jun GR, Stein TD
Alzheimer's research & therapy 2020 Sep 17;12(1):111
Alzheimer's research & therapy 2020 Sep 17;12(1):111
Glucosylpolyphenols as Inhibitors of Aβ-Induced Fyn Kinase Activation and Tau Phosphorylation: Synthesis, Membrane Permeability, and Exploratory Target Assessment within the Scope of Type 2 Diabetes and Alzheimer's Disease.
de Matos AM, Blázquez-Sánchez MT, Bento-Oliveira A, de Almeida RFM, Nunes R, Lopes PEM, Machuqueiro M, Cristóvão JS, Gomes CM, Souza CS, El Idrissi IG, Colabufo NA, Diniz A, Marcelo F, Oliveira MC, López Ó, Fernandez-Bolaños JG, Dätwyler P, Ernst B, Ning K, Garwood C, Chen B, Rauter AP
Journal of medicinal chemistry 2020 Oct 22;63(20):11663-11690
Journal of medicinal chemistry 2020 Oct 22;63(20):11663-11690
Rho-kinase ROCK inhibitors reduce oligomeric tau protein.
Hamano T, Shirafuji N, Yen SH, Yoshida H, Kanaan NM, Hayashi K, Ikawa M, Yamamura O, Fujita Y, Kuriyama M, Nakamoto Y
Neurobiology of aging 2020 May;89:41-54
Neurobiology of aging 2020 May;89:41-54
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schöll M, Massarweh G, Soucy JP, Höglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P, Blennow K
The Lancet. Neurology 2020 May;19(5):422-433
The Lancet. Neurology 2020 May;19(5):422-433
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia.
Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM, Stomrud E, Dage JL, Hansson O
Nature medicine 2020 Mar;26(3):379-386
Nature medicine 2020 Mar;26(3):379-386
Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization.
Dominguez-Meijide A, Vasili E, König A, Cima-Omori MS, Ibáñez de Opakua A, Leonov A, Ryazanov S, Zweckstetter M, Griesinger C, Outeiro TF
Scientific reports 2020 Jul 30;10(1):12827
Scientific reports 2020 Jul 30;10(1):12827
Serum Tau Proteins as Potential Biomarkers for the Assessment of Alzheimer's Disease Progression.
Nam E, Lee YB, Moon C, Chang KA
International journal of molecular sciences 2020 Jul 15;21(14)
International journal of molecular sciences 2020 Jul 15;21(14)
Highly sensitive quantification of Alzheimer's disease biomarkers by aptamer-assisted amplification.
Chan HN, Xu D, Ho SL, He D, Wong MS, Li HW
Theranostics 2019;9(10):2939-2949
Theranostics 2019;9(10):2939-2949
Hibernation Impairs Odor Discrimination - Implications for Alzheimer's Disease.
Bullmann T, Feneberg E, Kretzschmann TP, Ogunlade V, Holzer M, Arendt T
Frontiers in neuroanatomy 2019;13:69
Frontiers in neuroanatomy 2019;13:69
Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy.
Di Meco A, Li JG, Barrero C, Merali S, Praticò D
Molecular psychiatry 2019 Nov;24(11):1696-1706
Molecular psychiatry 2019 Nov;24(11):1696-1706
Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease.
Jadiya P, Kolmetzky DW, Tomar D, Di Meco A, Lombardi AA, Lambert JP, Luongo TS, Ludtmann MH, Praticò D, Elrod JW
Nature communications 2019 Aug 29;10(1):3885
Nature communications 2019 Aug 29;10(1):3885
MRI and histological evaluation of pulsed focused ultrasound and microbubbles treatment effects in the brain.
Kovacs ZI, Tu TW, Sundby M, Qureshi F, Lewis BK, Jikaria N, Burks SR, Frank JA
Theranostics 2018;8(17):4837-4855
Theranostics 2018;8(17):4837-4855
Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.
Turnbull MT, Boskovic Z, Coulson EJ
Frontiers in molecular neuroscience 2018;11:51
Frontiers in molecular neuroscience 2018;11:51
Lewy Body Pathology and Chronic Traumatic Encephalopathy Associated With Contact Sports.
Adams JW, Alvarez VE, Mez J, Huber BR, Tripodis Y, Xia W, Meng G, Kubilus CA, Cormier K, Kiernan PT, Daneshvar DH, Chua AS, Svirsky S, Nicks R, Abdolmohammadi B, Evers L, Solomon TM, Cherry JD, Aytan N, Mahar I, Devine S, Auerbach S, Alosco ML, Nowinski CJ, Kowall NW, Goldstein LE, Dwyer B, Katz DI, Cantu RC, Stern RA, Au R, McKee AC, Stein TD
Journal of neuropathology and experimental neurology 2018 Sep 1;77(9):757-768
Journal of neuropathology and experimental neurology 2018 Sep 1;77(9):757-768
Gain of toxic apolipoprotein E4 effects in human iPSC-derived neurons is ameliorated by a small-molecule structure corrector.
Wang C, Najm R, Xu Q, Jeong DE, Walker D, Balestra ME, Yoon SY, Yuan H, Li G, Miller ZA, Miller BL, Malloy MJ, Huang Y
Nature medicine 2018 May;24(5):647-657
Nature medicine 2018 May;24(5):647-657
The aged rhesus macaque manifests Braak stage III/IV Alzheimer's-like pathology.
Paspalas CD, Carlyle BC, Leslie S, Preuss TM, Crimins JL, Huttner AJ, van Dyck CH, Rosene DL, Nairn AC, Arnsten AFT
Alzheimer's & dementia : the journal of the Alzheimer's Association 2018 May;14(5):680-691
Alzheimer's & dementia : the journal of the Alzheimer's Association 2018 May;14(5):680-691
Loss of kallikrein-related peptidase 7 exacerbates amyloid pathology in Alzheimer's disease model mice.
Kidana K, Tatebe T, Ito K, Hara N, Kakita A, Saito T, Takatori S, Ouchi Y, Ikeuchi T, Makino M, Saido TC, Akishita M, Iwatsubo T, Hori Y, Tomita T
EMBO molecular medicine 2018 Mar;10(3)
EMBO molecular medicine 2018 Mar;10(3)
Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer's disease.
Borin M, Saraceno C, Catania M, Lorenzetto E, Pontelli V, Paterlini A, Fostinelli S, Avesani A, Di Fede G, Zanusso G, Benussi L, Binetti G, Zorzan S, Ghidoni R, Buffelli M, Bolognin S
Acta neuropathologica communications 2018 Jul 13;6(1):61
Acta neuropathologica communications 2018 Jul 13;6(1):61
A Conserved Cytoskeletal Signaling Cascade Mediates Neurotoxicity of FTDP-17 Tau Mutations In Vivo.
Bardai FH, Wang L, Mutreja Y, Yenjerla M, Gamblin TC, Feany MB
The Journal of neuroscience : the official journal of the Society for Neuroscience 2018 Jan 3;38(1):108-119
The Journal of neuroscience : the official journal of the Society for Neuroscience 2018 Jan 3;38(1):108-119
NAD(+) supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency.
Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, Zhang Y, Moritoh K, O'Connell JF, Baptiste BA, Stevnsner TV, Mattson MP, Bohr VA
Proceedings of the National Academy of Sciences of the United States of America 2018 Feb 20;115(8):E1876-E1885
Proceedings of the National Academy of Sciences of the United States of America 2018 Feb 20;115(8):E1876-E1885
Phosphorylation of nuclear Tau is modulated by distinct cellular pathways.
Ulrich G, Salvadè A, Boersema P, Calì T, Foglieni C, Sola M, Picotti P, Papin S, Paganetti P
Scientific reports 2018 Dec 7;8(1):17702
Scientific reports 2018 Dec 7;8(1):17702
Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography.
Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, Airey DC, Knopman DS, Roberts RO, Machulda MM, Jack CR Jr, Petersen RC, Dage JL
Alzheimer's & dementia : the journal of the Alzheimer's Association 2018 Aug;14(8):989-997
Alzheimer's & dementia : the journal of the Alzheimer's Association 2018 Aug;14(8):989-997
Tau secretion is correlated to an increase of Golgi dynamics.
Mohamed NV, Desjardins A, Leclerc N
PloS one 2017;12(5):e0178288
PloS one 2017;12(5):e0178288
Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects.
Lathuilière A, Valdés P, Papin S, Cacquevel M, Maclachlan C, Knott GW, Muhs A, Paganetti P, Schneider BL
Scientific reports 2017 Oct 19;7(1):13556
Scientific reports 2017 Oct 19;7(1):13556
Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.
Chanu SI, Sarkar S
Molecular neurobiology 2017 May;54(4):2706-2719
Molecular neurobiology 2017 May;54(4):2706-2719
Rab7A regulates tau secretion.
Rodriguez L, Mohamed NV, Desjardins A, Lippé R, Fon EA, Leclerc N
Journal of neurochemistry 2017 May;141(4):592-605
Journal of neurochemistry 2017 May;141(4):592-605
Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology.
Li JG, Barrero C, Merali S, Praticò D
Human molecular genetics 2017 May 15;26(10):1855-1862
Human molecular genetics 2017 May 15;26(10):1855-1862
A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy.
Trzeciakiewicz H, Tseng JH, Wander CM, Madden V, Tripathy A, Yuan CX, Cohen TJ
Scientific reports 2017 Mar 13;7:44102
Scientific reports 2017 Mar 13;7:44102
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.
Dourlen P, Fernandez-Gomez FJ, Dupont C, Grenier-Boley B, Bellenguez C, Obriot H, Caillierez R, Sottejeau Y, Chapuis J, Bretteville A, Abdelfettah F, Delay C, Malmanche N, Soininen H, Hiltunen M, Galas MC, Amouyel P, Sergeant N, Buée L, Lambert JC, Dermaut B
Molecular psychiatry 2017 Jun;22(6):874-883
Molecular psychiatry 2017 Jun;22(6):874-883
12/15-Lipoxygenase Inhibition Reverses Cognitive Impairment, Brain Amyloidosis, and Tau Pathology by Stimulating Autophagy in Aged Triple Transgenic Mice.
Di Meco A, Li JG, Blass BE, Abou-Gharbia M, Lauretti E, Praticò D
Biological psychiatry 2017 Jan 15;81(2):92-100
Biological psychiatry 2017 Jan 15;81(2):92-100
Effect of canola oil consumption on memory, synapse and neuropathology in the triple transgenic mouse model of Alzheimer's disease.
Lauretti E, Praticò D
Scientific reports 2017 Dec 7;7(1):17134
Scientific reports 2017 Dec 7;7(1):17134
Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: role of autophagy.
Lauretti E, Iuliano L, Praticò D
Annals of clinical and translational neurology 2017 Aug;4(8):564-574
Annals of clinical and translational neurology 2017 Aug;4(8):564-574
Accelerated aging exacerbates a pre-existing pathology in a tau transgenic mouse model.
Bodea LG, Evans HT, Van der Jeugd A, Ittner LM, Delerue F, Kril J, Halliday G, Hodges J, Kiernan MC, Götz J
Aging cell 2017 Apr;16(2):377-386
Aging cell 2017 Apr;16(2):377-386
Five lipoxygenase hypomethylation mediates the homocysteine effect on Alzheimer's phenotype.
Li JG, Barrero C, Merali S, Praticò D
Scientific reports 2017 Apr 6;7:46002
Scientific reports 2017 Apr 6;7:46002
Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction.
Yetman MJ, Fowler SW, Jankowsky JL
PloS one 2016;11(4):e0153724
PloS one 2016;11(4):e0153724
miR-132 loss de-represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain.
Salta E, Sierksma A, Vanden Eynden E, De Strooper B
EMBO molecular medicine 2016 Sep;8(9):1005-18
EMBO molecular medicine 2016 Sep;8(9):1005-18
Dendritic Spine Loss and Chronic White Matter Inflammation in a Mouse Model of Highly Repetitive Head Trauma.
Winston CN, Noël A, Neustadtl A, Parsadanian M, Barton DJ, Chellappa D, Wilkins TE, Alikhani AD, Zapple DN, Villapol S, Planel E, Burns MP
The American journal of pathology 2016 Mar;186(3):552-67
The American journal of pathology 2016 Mar;186(3):552-67
Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner.
Polanco JC, Scicluna BJ, Hill AF, Götz J
The Journal of biological chemistry 2016 Jun 10;291(24):12445-12466
The Journal of biological chemistry 2016 Jun 10;291(24):12445-12466
The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments.
Nishikawa T, Takahashi T, Nakamori M, Hosomi N, Maruyama H, Miyazaki Y, Izumi Y, Matsumoto M
Neuropathology and applied neurobiology 2016 Dec;42(7):639-653
Neuropathology and applied neurobiology 2016 Dec;42(7):639-653
Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models.
Lipton SA, Rezaie T, Nutter A, Lopez KM, Parker J, Kosaka K, Satoh T, McKercher SR, Masliah E, Nakanishi N
Cell death & disease 2016 Dec 1;7(12):e2499
Cell death & disease 2016 Dec 1;7(12):e2499
Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model.
Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH, Medeiros R
Journal of Alzheimer's disease : JAD 2015;43(3):893-903
Journal of Alzheimer's disease : JAD 2015;43(3):893-903
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
Sankaranarayanan S, Barten DM, Vana L, Devidze N, Yang L, Cadelina G, Hoque N, DeCarr L, Keenan S, Lin A, Cao Y, Snyder B, Zhang B, Nitla M, Hirschfeld G, Barrezueta N, Polson C, Wes P, Rangan VS, Cacace A, Albright CF, Meredith J Jr, Trojanowski JQ, Lee VM, Brunden KR, Ahlijanian M
PloS one 2015;10(5):e0125614
PloS one 2015;10(5):e0125614
Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.
Riise J, Plath N, Pakkenberg B, Parachikova A
Journal of neural transmission (Vienna, Austria : 1996) 2015 Sep;122(9):1303-18
Journal of neural transmission (Vienna, Austria : 1996) 2015 Sep;122(9):1303-18
Physiologically relevant factors influence tau phosphorylation by leucine-rich repeat kinase 2.
Hamm M, Bailey R, Shaw G, Yen SH, Lewis J, Giasson BI
Journal of neuroscience research 2015 Oct;93(10):1567-80
Journal of neuroscience research 2015 Oct;93(10):1567-80
Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy.
Hunt JB Jr, Nash KR, Placides D, Moran P, Selenica ML, Abuqalbeen F, Ratnasamy K, Slouha N, Rodriguez-Ospina S, Savlia M, Ranaweera Y, Reid P, Dickey CA, Uricia R, Yang CG, Sandusky LA, Gordon MN, Morgan D, Lee DC
The Journal of neuroscience : the official journal of the Society for Neuroscience 2015 Nov 4;35(44):14842-60
The Journal of neuroscience : the official journal of the Society for Neuroscience 2015 Nov 4;35(44):14842-60
HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.
Sepulveda-Diaz JE, Alavi Naini SM, Huynh MB, Ouidja MO, Yanicostas C, Chantepie S, Villares J, Lamari F, Jospin E, van Kuppevelt TH, Mensah-Nyagan AG, Raisman-Vozari R, Soussi-Yanicostas N, Papy-Garcia D
Brain : a journal of neurology 2015 May;138(Pt 5):1339-54
Brain : a journal of neurology 2015 May;138(Pt 5):1339-54
Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology.
Song L, Lu SX, Ouyang X, Melchor J, Lee J, Terracina G, Wang X, Hyde L, Hess JF, Parker EM, Zhang L
Molecular neurodegeneration 2015 Mar 26;10:14
Molecular neurodegeneration 2015 Mar 26;10:14
Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
Ittner A, Bertz J, Suh LS, Stevens CH, Götz J, Ittner LM
Journal of neurochemistry 2015 Jan;132(1):135-45
Journal of neurochemistry 2015 Jan;132(1):135-45
Modulation of AD neuropathology and memory impairments by the isoprostane F2α is mediated by the thromboxane receptor.
Lauretti E, Di Meco A, Chu J, Praticò D
Neurobiology of aging 2015 Feb;36(2):812-20
Neurobiology of aging 2015 Feb;36(2):812-20
Glucose deprivation increases tau phosphorylation via P38 mitogen-activated protein kinase.
Lauretti E, Praticò D
Aging cell 2015 Dec;14(6):1067-74
Aging cell 2015 Dec;14(6):1067-74
Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions.
Petry FR, Pelletier J, Bretteville A, Morin F, Calon F, Hébert SS, Whittington RA, Planel E
PloS one 2014;9(5):e94251
PloS one 2014;9(5):e94251
Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
Kan SH, Aoyagi-Scharber M, Le SQ, Vincelette J, Ohmi K, Bullens S, Wendt DJ, Christianson TM, Tiger PM, Brown JR, Lawrence R, Yip BK, Holtzinger J, Bagri A, Crippen-Harmon D, Vondrak KN, Chen Z, Hague CM, Woloszynek JC, Cheung DS, Webster KA, Adintori EG, Lo MJ, Wong W, Fitzpatrick PA, LeBowitz JH, Crawford BE, Bunting S, Dickson PI, Neufeld EF
Proceedings of the National Academy of Sciences of the United States of America 2014 Oct 14;111(41):14870-5
Proceedings of the National Academy of Sciences of the United States of America 2014 Oct 14;111(41):14870-5
Age-related downregulation of the CaV3.1 T-type calcium channel as a mediator of amyloid beta production.
Rice RA, Berchtold NC, Cotman CW, Green KN
Neurobiology of aging 2014 May;35(5):1002-11
Neurobiology of aging 2014 May;35(5):1002-11
Site-specific phosphorylation of Tau protein is associated with deacetylation of microtubules in mouse spermatogenic cells during meiosis.
Inoue H, Hiradate Y, Shirakata Y, Kanai K, Kosaka K, Gotoh A, Fukuda Y, Nakai Y, Uchida T, Sato E, Tanemura K
FEBS letters 2014 May 29;588(11):2003-8
FEBS letters 2014 May 29;588(11):2003-8
Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.
Kondadi AK, Wang S, Montagner S, Kladt N, Korwitz A, Martinelli P, Herholz D, Baker MJ, Schauss AC, Langer T, Rugarli EI
The EMBO journal 2014 May 2;33(9):1011-26
The EMBO journal 2014 May 2;33(9):1011-26
Annonacin, a natural lipophilic mitochondrial complex I inhibitor, increases phosphorylation of tau in the brain of FTDP-17 transgenic mice.
Yamada ES, Respondek G, Müssner S, de Andrade A, Höllerhage M, Depienne C, Rastetter A, Tarze A, Friguet B, Salama M, Champy P, Oertel WH, Höglinger GU
Experimental neurology 2014 Mar;253:113-25
Experimental neurology 2014 Mar;253:113-25
Genetic ablation of tau mitigates cognitive impairment induced by type 1 diabetes.
Abbondante S, Baglietto-Vargas D, Rodriguez-Ortiz CJ, Estrada-Hernandez T, Medeiros R, Laferla FM
The American journal of pathology 2014 Mar;184(3):819-26
The American journal of pathology 2014 Mar;184(3):819-26
Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles.
Li JG, Chu J, Barrero C, Merali S, Praticò D
Annals of neurology 2014 Jun;75(6):851-63
Annals of neurology 2014 Jun;75(6):851-63
Endogenous murine tau promotes neurofibrillary tangles in 3xTg-AD mice without affecting cognition.
Baglietto-Vargas D, Kitazawa M, Le EJ, Estrada-Hernandez T, Rodriguez-Ortiz CJ, Medeiros R, Green KN, LaFerla FM
Neurobiology of disease 2014 Feb;62:407-15
Neurobiology of disease 2014 Feb;62:407-15
α7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles.
Medeiros R, Castello NA, Cheng D, Kitazawa M, Baglietto-Vargas D, Green KN, Esbenshade TA, Bitner RS, Decker MW, LaFerla FM
The American journal of pathology 2014 Feb;184(2):520-9
The American journal of pathology 2014 Feb;184(2):520-9
Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.
Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E
British journal of pharmacology 2014 Dec;171(24):5757-73
British journal of pharmacology 2014 Dec;171(24):5757-73
Sleep deprivation impairs memory, tau metabolism, and synaptic integrity of a mouse model of Alzheimer's disease with plaques and tangles.
Di Meco A, Joshi YB, Praticò D
Neurobiology of aging 2014 Aug;35(8):1813-20
Neurobiology of aging 2014 Aug;35(8):1813-20
Visualizing the microtubule-associated protein tau in the nucleus.
Lu J, Li T, He R, Bartlett PF, Götz J
Science China. Life sciences 2014 Apr;57(4):422-31
Science China. Life sciences 2014 Apr;57(4):422-31
Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem.
Rüb U, Hentschel M, Stratmann K, Brunt E, Heinsen H, Seidel K, Bouzrou M, Auburger G, Paulson H, Vonsattel JP, Lange H, Korf HW, den Dunnen W
Brain pathology (Zurich, Switzerland) 2014 Apr;24(3):247-60
Brain pathology (Zurich, Switzerland) 2014 Apr;24(3):247-60
Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of Aβ and tau.
Guo Q, Li H, Cole AL, Hur JY, Li Y, Zheng H
PloS one 2013;8(11):e80706
PloS one 2013;8(11):e80706
Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.
Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF
PloS one 2013;8(10):e76523
PloS one 2013;8(10):e76523
SorLA deficiency dissects amyloid pathology from tau and cholinergic neurodegeneration in a mouse model of Alzheimer's disease.
Capsoni S, Carlo AS, Vignone D, Amato G, Criscuolo C, Willnow TE, Cattaneo A
Journal of Alzheimer's disease : JAD 2013;33(2):357-71
Journal of Alzheimer's disease : JAD 2013;33(2):357-71
Elevated levels of soluble total and hyperphosphorylated tau result in early behavioral deficits and distinct changes in brain pathology in a new tau transgenic mouse model.
Flunkert S, Hierzer M, Löffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B
Neuro-degenerative diseases 2013;11(4):194-205
Neuro-degenerative diseases 2013;11(4):194-205
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.
Baglietto-Vargas D, Medeiros R, Martinez-Coria H, LaFerla FM, Green KN
Biological psychiatry 2013 Sep 1;74(5):357-66
Biological psychiatry 2013 Sep 1;74(5):357-66
Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice.
Leboucher A, Laurent C, Fernandez-Gomez FJ, Burnouf S, Troquier L, Eddarkaoui S, Demeyer D, Caillierez R, Zommer N, Vallez E, Bantubungi K, Breton C, Pigny P, Buée-Scherrer V, Staels B, Hamdane M, Tailleux A, Buée L, Blum D
Diabetes 2013 May;62(5):1681-8
Diabetes 2013 May;62(5):1681-8
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy.
Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN, Morgan D
Neurobiology of aging 2013 Jun;34(6):1540-8
Neurobiology of aging 2013 Jun;34(6):1540-8
Clinical correlates in an experimental model of repetitive mild brain injury.
Mannix R, Meehan WP, Mandeville J, Grant PE, Gray T, Berglass J, Zhang J, Bryant J, Rezaie S, Chung JY, Peters NV, Lee C, Tien LW, Kaplan DL, Feany M, Whalen M
Annals of neurology 2013 Jul;74(1):65-75
Annals of neurology 2013 Jul;74(1):65-75
Ankyrin-B structurally defines terminal microdomains of peripheral somatosensory axons.
Engelhardt M, Vorwald S, Sobotzik JM, Bennett V, Schultz C
Brain structure & function 2013 Jul;218(4):1005-16
Brain structure & function 2013 Jul;218(4):1005-16
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model.
Burnouf S, Martire A, Derisbourg M, Laurent C, Belarbi K, Leboucher A, Fernandez-Gomez FJ, Troquier L, Eddarkaoui S, Grosjean ME, Demeyer D, Muhr-Tailleux A, Buisson A, Sergeant N, Hamdane M, Humez S, Popoli P, Buée L, Blum D
Aging cell 2013 Feb;12(1):11-23
Aging cell 2013 Feb;12(1):11-23
Sex-dependent alterations in social behaviour and cortical synaptic activity coincide at different ages in a model of Alzheimer's disease.
Bories C, Guitton MJ, Julien C, Tremblay C, Vandal M, Msaid M, De Koninck Y, Calon F
PloS one 2012;7(9):e46111
PloS one 2012;7(9):e46111
Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology.
Castello NA, Green KN, LaFerla FM
PloS one 2012;7(8):e39566
PloS one 2012;7(8):e39566
Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice.
Schön C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S, Seeliger MW, Arzberger T, Goedert M, Kretzschmar HA, Schmidt B, Herms J
PloS one 2012;7(12):e53547
PloS one 2012;7(12):e53547
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth.
Kawakami F, Yabata T, Ohta E, Maekawa T, Shimada N, Suzuki M, Maruyama H, Ichikawa T, Obata F
PloS one 2012;7(1):e30834
PloS one 2012;7(1):e30834
Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease.
Joshi YB, Chu J, Praticò D
Journal of Alzheimer's disease : JAD 2012;31(1):167-76
Journal of Alzheimer's disease : JAD 2012;31(1):167-76
Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors.
Bretteville A, Marcouiller F, Julien C, El Khoury NB, Petry FR, Poitras I, Mouginot D, Lévesque G, Hébert SS, Planel E
Scientific reports 2012;2:480
Scientific reports 2012;2:480
Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway.
Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, Komatsu M, Abeliovich A
Molecular neurodegeneration 2012 Sep 21;7:48
Molecular neurodegeneration 2012 Sep 21;7:48
Hippocampal BDNF expression in a tau transgenic mouse model.
Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A, Laurent C, Hamdane M, Buee L, Blum D
Current Alzheimer research 2012 May;9(4):406-10
Current Alzheimer research 2012 May;9(4):406-10
Hippocampal BDNF expression in a tau transgenic mouse model.
Burnouf S, Belarbi K, Troquier L, Derisbourg M, Demeyer D, Leboucher A, Laurent C, Hamdane M, Buee L, Blum D
Current Alzheimer research 2012 May;9(4):406-10
Current Alzheimer research 2012 May;9(4):406-10
Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates.
Löffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, Hutter-Paier B
Journal of molecular neuroscience : MN 2012 May;47(1):192-203
Journal of molecular neuroscience : MN 2012 May;47(1):192-203
Increased cerebrospinal fluid levels of double-stranded RNA-dependant protein kinase in Alzheimer's disease.
Mouton-Liger F, Paquet C, Dumurgier J, Lapalus P, Gray F, Laplanche JL, Hugon J, Groupe d'Investigation du Liquide Céphalorachidien Study Network
Biological psychiatry 2012 May 1;71(9):829-35
Biological psychiatry 2012 May 1;71(9):829-35
Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models.
Jones NC, Nguyen T, Corcoran NM, Velakoulis D, Chen T, Grundy R, O'Brien TJ, Hovens CM
Neurobiology of disease 2012 Mar;45(3):897-901
Neurobiology of disease 2012 Mar;45(3):897-901
Ultrastructural alterations of Alzheimer's disease paired helical filaments by grape seed-derived polyphenols.
Ksiezak-Reding H, Ho L, Santa-Maria I, Diaz-Ruiz C, Wang J, Pasinetti GM
Neurobiology of aging 2012 Jul;33(7):1427-39
Neurobiology of aging 2012 Jul;33(7):1427-39
Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
Wang HY, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah SM, Burns LH
The Journal of neuroscience : the official journal of the Society for Neuroscience 2012 Jul 18;32(29):9773-84
The Journal of neuroscience : the official journal of the Society for Neuroscience 2012 Jul 18;32(29):9773-84
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice.
Medeiros R, Kitazawa M, Chabrier MA, Cheng D, Baglietto-Vargas D, Kling A, Moeller A, Green KN, LaFerla FM
The American journal of pathology 2012 Aug;181(2):616-25
The American journal of pathology 2012 Aug;181(2):616-25
Fyn knock-down increases Aβ, decreases phospho-tau, and worsens spatial learning in 3×Tg-AD mice.
Minami SS, Clifford TG, Hoe HS, Matsuoka Y, Rebeck GW
Neurobiology of aging 2012 Apr;33(4):825.e15-24
Neurobiology of aging 2012 Apr;33(4):825.e15-24
The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies.
Nijholt DA, van Haastert ES, Rozemuller AJ, Scheper W, Hoozemans JJ
The Journal of pathology 2012 Apr;226(5):693-702
The Journal of pathology 2012 Apr;226(5):693-702
Defects in the medial entorhinal cortex and dentate gyrus in the mouse model of Sanfilippo syndrome type B.
Ohmi K, Zhao HZ, Neufeld EF
PloS one 2011;6(11):e27461
PloS one 2011;6(11):e27461
Endogenous conversion of omega-6 into omega-3 fatty acids improves neuropathology in an animal model of Alzheimer's disease.
Lebbadi M, Julien C, Phivilay A, Tremblay C, Emond V, Kang JX, Calon F
Journal of Alzheimer's disease : JAD 2011;27(4):853-69
Journal of Alzheimer's disease : JAD 2011;27(4):853-69
Long term changes in phospho-APP and tau aggregation in the 3xTg-AD mice following cerebral ischemia.
Koike MA, Garcia FG, Kitazawa M, Green KN, Laferla FM
Neuroscience letters 2011 May 9;495(1):55-9
Neuroscience letters 2011 May 9;495(1):55-9
Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice.
Kudo LC, Parfenova L, Ren G, Vi N, Hui M, Ma Z, Lau K, Gray M, Bardag-Gorce F, Wiedau-Pazos M, Hui KS, Karsten SL
Human molecular genetics 2011 May 1;20(9):1820-33
Human molecular genetics 2011 May 1;20(9):1820-33
Modulation of tau phosphorylation by the kinase PKR: implications in Alzheimer's disease.
Bose A, Mouton-Liger F, Paquet C, Mazot P, Vigny M, Gray F, Hugon J
Brain pathology (Zurich, Switzerland) 2011 Mar;21(2):189-200
Brain pathology (Zurich, Switzerland) 2011 Mar;21(2):189-200
Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ
Journal of neuroscience research 2011 Jun;89(6):822-32
Journal of neuroscience research 2011 Jun;89(6):822-32
The physiological link between metabolic rate depression and tau phosphorylation in mammalian hibernation.
Stieler JT, Bullmann T, Kohl F, Tøien Ø, Brückner MK, Härtig W, Barnes BM, Arendt T
PloS one 2011 Jan 18;6(1):e14530
PloS one 2011 Jan 18;6(1):e14530
A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice.
Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y
PloS one 2011 Jan 17;6(1):e16259
PloS one 2011 Jan 17;6(1):e16259
The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner.
Gauthier-Kemper A, Weissmann C, Golovyashkina N, Sebö-Lemke Z, Drewes G, Gerke V, Heinisch JJ, Brandt R
The Journal of cell biology 2011 Feb 21;192(4):647-61
The Journal of cell biology 2011 Feb 21;192(4):647-61
Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant.
Sydow A, Van der Jeugd A, Zheng F, Ahmed T, Balschun D, Petrova O, Drexler D, Zhou L, Rune G, Mandelkow E, D'Hooge R, Alzheimer C, Mandelkow EM
The Journal of neuroscience : the official journal of the Society for Neuroscience 2011 Feb 16;31(7):2511-25
The Journal of neuroscience : the official journal of the Society for Neuroscience 2011 Feb 16;31(7):2511-25
A peculiar constellation of tau pathology defines a subset of dementia in the elderly.
Kovacs GG, Molnár K, László L, Ströbel T, Botond G, Hönigschnabl S, Reiner-Concin A, Palkovits M, Fischer P, Budka H
Acta neuropathologica 2011 Aug;122(2):205-22
Acta neuropathologica 2011 Aug;122(2):205-22
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration.
Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ
Proceedings of the National Academy of Sciences of the United States of America 2011 Apr 5;108(14):5819-24
Proceedings of the National Academy of Sciences of the United States of America 2011 Apr 5;108(14):5819-24
The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease.
Liu D, Pitta M, Lee JH, Ray B, Lahiri DK, Furukawa K, Mughal M, Jiang H, Villarreal J, Cutler RG, Greig NH, Mattson MP
Journal of Alzheimer's disease : JAD 2010;22(2):443-57
Journal of Alzheimer's disease : JAD 2010;22(2):443-57
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation.
Parachikova A, Vasilevko V, Cribbs DH, LaFerla FM, Green KN
Journal of Alzheimer's disease : JAD 2010;21(2):527-42
Journal of Alzheimer's disease : JAD 2010;21(2):527-42
A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model.
Hurtado DE, Molina-Porcel L, Iba M, Aboagye AK, Paul SM, Trojanowski JQ, Lee VM
The American journal of pathology 2010 Oct;177(4):1977-88
The American journal of pathology 2010 Oct;177(4):1977-88
Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to Aβ oligomers accumulation.
Caccamo A, Magrí A, Oddo S
Molecular neurodegeneration 2010 Nov 11;5:51
Molecular neurodegeneration 2010 Nov 11;5:51
Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice.
Vale C, Alonso E, Rubiolo JA, Vieytes MR, LaFerla FM, Giménez-Llort L, Botana LM
Cellular and molecular neurobiology 2010 May;30(4):577-90
Cellular and molecular neurobiology 2010 May;30(4):577-90
CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy.
Zilka N, Korenova M, Kovacech B, Iqbal K, Novak M
Acta neuropathologica 2010 Jun;119(6):679-87
Acta neuropathologica 2010 Jun;119(6):679-87
Co-occurrence of Alzheimer's disease ß-amyloid and τ pathologies at synapses.
Takahashi RH, Capetillo-Zarate E, Lin MT, Milner TA, Gouras GK
Neurobiology of aging 2010 Jul;31(7):1145-52
Neurobiology of aging 2010 Jul;31(7):1145-52
Oligemic hypoperfusion differentially affects tau and amyloid-{beta}.
Koike MA, Green KN, Blurton-Jones M, Laferla FM
The American journal of pathology 2010 Jul;177(1):300-10
The American journal of pathology 2010 Jul;177(1):300-10
Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo.
Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, Tyynelä J, Scherzer CR, Feany MB
PLoS genetics 2010 Jul 15;6(7):e1001026
PLoS genetics 2010 Jul 15;6(7):e1001026
Caprospinol reduces amyloid deposits and improves cognitive function in a rat model of Alzheimer's disease.
Lecanu L, Rammouz G, McCourty A, Sidahmed EK, Greeson J, Papadopoulos V
Neuroscience 2010 Jan 20;165(2):427-35
Neuroscience 2010 Jan 20;165(2):427-35
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.
Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM
The American journal of pathology 2010 Feb;176(2):870-80
The American journal of pathology 2010 Feb;176(2):870-80
Glial fibrillary tangles and JAK/STAT-mediated glial and neuronal cell death in a Drosophila model of glial tauopathy.
Colodner KJ, Feany MB
The Journal of neuroscience : the official journal of the Society for Neuroscience 2010 Dec 1;30(48):16102-13
The Journal of neuroscience : the official journal of the Society for Neuroscience 2010 Dec 1;30(48):16102-13
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models.
van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Götz J, Ittner LM
Proceedings of the National Academy of Sciences of the United States of America 2010 Aug 3;107(31):13888-93
Proceedings of the National Academy of Sciences of the United States of America 2010 Aug 3;107(31):13888-93
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.
Caccamo A, Majumder S, Richardson A, Strong R, Oddo S
The Journal of biological chemistry 2010 Apr 23;285(17):13107-20
The Journal of biological chemistry 2010 Apr 23;285(17):13107-20
Anesthesia induces phosphorylation of tau.
Run X, Liang Z, Zhang L, Iqbal K, Grundke-Iqbal I, Gong CX
Journal of Alzheimer's disease : JAD 2009;16(3):619-26
Journal of Alzheimer's disease : JAD 2009;16(3):619-26
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains.
van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, Gregory GC, Halliday GM, Götz J, Kril JJ, Ittner LM
Journal of neural transmission (Vienna, Austria : 1996) 2009 Oct;116(10):1243-51
Journal of neural transmission (Vienna, Austria : 1996) 2009 Oct;116(10):1243-51
AnkyrinG is required to maintain axo-dendritic polarity in vivo.
Sobotzik JM, Sie JM, Politi C, Del Turco D, Bennett V, Deller T, Schultz C
Proceedings of the National Academy of Sciences of the United States of America 2009 Oct 13;106(41):17564-9
Proceedings of the National Academy of Sciences of the United States of America 2009 Oct 13;106(41):17564-9
Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy.
Ohmi K, Kudo LC, Ryazantsev S, Zhao HZ, Karsten SL, Neufeld EF
Proceedings of the National Academy of Sciences of the United States of America 2009 May 19;106(20):8332-7
Proceedings of the National Academy of Sciences of the United States of America 2009 May 19;106(20):8332-7
Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly.
Woltjer RL, Sonnen JA, Sokal I, Rung LG, Yang W, Kjerulf JD, Klingert D, Johnson C, Rhew I, Tsuang D, Crane PK, Larson EB, Montine TJ
Brain pathology (Zurich, Switzerland) 2009 Jul;19(3):365-74
Brain pathology (Zurich, Switzerland) 2009 Jul;19(3):365-74
Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease.
Ittner LM, Ke YD, Götz J
The Journal of biological chemistry 2009 Jul 31;284(31):20909-16
The Journal of biological chemistry 2009 Jul 31;284(31):20909-16
The excitotoxin quinolinic acid induces tau phosphorylation in human neurons.
Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ
PloS one 2009 Jul 22;4(7):e6344
PloS one 2009 Jul 22;4(7):e6344
A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau.
Brandt R, Gergou A, Wacker I, Fath T, Hutter H
Neurobiology of aging 2009 Jan;30(1):22-33
Neurobiology of aging 2009 Jan;30(1):22-33
Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model.
Chatterjee S, Sang TK, Lawless GM, Jackson GR
Human molecular genetics 2009 Jan 1;18(1):164-77
Human molecular genetics 2009 Jan 1;18(1):164-77
Development of a non invasive NGF-based therapy for Alzheimer's disease.
Covaceuszach S, Capsoni S, Ugolini G, Spirito F, Vignone D, Cattaneo A
Current Alzheimer research 2009 Apr;6(2):158-70
Current Alzheimer research 2009 Apr;6(2):158-70
Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation.
Song MS, Rauw G, Baker GB, Kar S
The European journal of neuroscience 2008 Nov;28(10):1989-2002
The European journal of neuroscience 2008 Nov;28(10):1989-2002
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy.
Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, Sun A, Finn G, Pastorino L, Lee VM, Lu KP
The Journal of clinical investigation 2008 May;118(5):1877-89
The Journal of clinical investigation 2008 May;118(5):1877-89
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice.
Mastrangelo MA, Bowers WJ
BMC neuroscience 2008 Aug 12;9:81
BMC neuroscience 2008 Aug 12;9:81
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS
The Journal of pharmacology and experimental therapeutics 2008 Apr;325(1):146-53
The Journal of pharmacology and experimental therapeutics 2008 Apr;325(1):146-53
Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.
Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J
British journal of pharmacology 2007 Nov;152(6):959-79
British journal of pharmacology 2007 Nov;152(6):959-79
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.
Caccamo A, Oddo S, Tran LX, LaFerla FM
The American journal of pathology 2007 May;170(5):1669-75
The American journal of pathology 2007 May;170(5):1669-75
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies.
Luo W, Dou F, Rodina A, Chip S, Kim J, Zhao Q, Moulick K, Aguirre J, Wu N, Greengard P, Chiosis G
Proceedings of the National Academy of Sciences of the United States of America 2007 May 29;104(22):9511-6
Proceedings of the National Academy of Sciences of the United States of America 2007 May 29;104(22):9511-6
Oxidative stress mediates tau-induced neurodegeneration in Drosophila.
Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB
The Journal of clinical investigation 2007 Jan;117(1):236-45
The Journal of clinical investigation 2007 Jan;117(1):236-45
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM
Journal of neurochemistry 2007 Aug;102(4):1053-63
Journal of neurochemistry 2007 Aug;102(4):1053-63
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels.
Green KN, Martinez-Coria H, Khashwji H, Hall EB, Yurko-Mauro KA, Ellis L, LaFerla FM
The Journal of neuroscience : the official journal of the Society for Neuroscience 2007 Apr 18;27(16):4385-95
The Journal of neuroscience : the official journal of the Society for Neuroscience 2007 Apr 18;27(16):4385-95
Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices.
Shahani N, Subramaniam S, Wolf T, Tackenberg C, Brandt R
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 May 31;26(22):6103-14
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 May 31;26(22):6103-14
The low density lipoprotein receptor-related protein 6 interacts with glycogen synthase kinase 3 and attenuates activity.
Mi K, Dolan PJ, Johnson GV
The Journal of biological chemistry 2006 Feb 24;281(8):4787-94
The Journal of biological chemistry 2006 Feb 24;281(8):4787-94
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease.
Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Aug 30;26(35):9047-56
The Journal of neuroscience : the official journal of the Society for Neuroscience 2006 Aug 30;26(35):9047-56
FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation.
Stoothoff WH, Cho JH, McDonald RP, Johnson GV
The Journal of biological chemistry 2005 Jan 7;280(1):270-6
The Journal of biological chemistry 2005 Jan 7;280(1):270-6
Lithium can relieve translational repression of TOP mRNAs elicited by various blocks along the cell cycle in a glycogen synthase kinase-3- and S6-kinase-independent manner.
Stolovich M, Lerer T, Bolkier Y, Cohen H, Meyuhas O
The Journal of biological chemistry 2005 Feb 18;280(7):5336-42
The Journal of biological chemistry 2005 Feb 18;280(7):5336-42
Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004 Mar 10;24(10):2527-34
The Journal of neuroscience : the official journal of the Society for Neuroscience 2004 Mar 10;24(10):2527-34
Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules.
Cho JH, Johnson GV
Journal of neurochemistry 2004 Jan;88(2):349-58
Journal of neurochemistry 2004 Jan;88(2):349-58
Mutant (R406W) human tau is hyperphosphorylated and does not efficiently bind microtubules in a neuronal cortical cell model.
Krishnamurthy PK, Johnson GV
The Journal of biological chemistry 2004 Feb 27;279(9):7893-900
The Journal of biological chemistry 2004 Feb 27;279(9):7893-900
Glycogen synthase kinase 3 beta induces caspase-cleaved tau aggregation in situ.
Cho JH, Johnson GV
The Journal of biological chemistry 2004 Dec 24;279(52):54716-23
The Journal of biological chemistry 2004 Dec 24;279(52):54716-23
Tau assembly in inducible transfectants expressing wild-type or FTDP-17 tau.
DeTure M, Ko LW, Easson C, Yen SH
The American journal of pathology 2002 Nov;161(5):1711-22
The American journal of pathology 2002 Nov;161(5):1711-22
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH
Journal of neurochemistry 2002 Dec;83(6):1498-508
Journal of neurochemistry 2002 Dec;83(6):1498-508
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.
Sahara N, Lewis J, DeTure M, McGowan E, Dickson DW, Hutton M, Yen SH
Journal of neurochemistry 2002 Dec;83(6):1498-508
Journal of neurochemistry 2002 Dec;83(6):1498-508
Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats.
Yoshida H, Goedert M
Biochemistry 2002 Dec 24;41(51):15203-11
Biochemistry 2002 Dec 24;41(51):15203-11
Molecular cloning and functional characterization of chicken brain tau: isoforms with up to five tandem repeats.
Yoshida H, Goedert M
Biochemistry 2002 Dec 24;41(51):15203-11
Biochemistry 2002 Dec 24;41(51):15203-11
Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.
Huang Y, Liu XQ, Wyss-Coray T, Brecht WJ, Sanan DA, Mahley RW
Proceedings of the National Academy of Sciences of the United States of America 2001 Jul 17;98(15):8838-43
Proceedings of the National Academy of Sciences of the United States of America 2001 Jul 17;98(15):8838-43
Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein.
Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Vandermeeren M, Cras P
The Biochemical journal 1994 Aug 1;301 ( Pt 3):871-7
The Biochemical journal 1994 Aug 1;301 ( Pt 3):871-7
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 5 Tau phosphorylation is decreased in neurons treated with 20 mM KCl. Immunoblot analysis of Tau phosphorylation in neurons treated either with 10mM or 20mM KCl. The phosphorylation of S199/S202, T181, T205 and S404 was not significantly affected by 10mM of KCl treatment whereas the phosphorylation of all these sites was decreased by 20mM of KCl treatment. The signal of the phospho-antibodies was normalized to that of total Tau (n = 5, mean +- SEM, unpaired t-test two-tailed, * P < 0.05, *** P < 0.001). The amount of dephosphorylated Tau revealed by the Tau-1 antibody was normalized to that of total Tau lysate (n = 5, mean +- SEM, unpaired t-test two-tailed, * P < 0.05).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 In vitro biochemical interaction between PTK2B and Tau. ( a ) Pull down of PTK2B with GST, GST-Tau1N4R and GST-Tau2N4R protein constructs. Upper panel: detection of PTK2B in the pull down extract by western blotting. Lower panel: corresponding Coomassie blue gel used as loading control of GST constructs. ( b ) Pull down of Tau1N4R and Tau2N4R with GST and GST-PTK2B protein constructs. Upper panel: detection of Tau (arrows) in the pull down extract by western blotting (an unspecific band is labeled with a star, MW, molecular weight). Lower panel: corresponding Coomassie blue gel used as loading control of GST constructs. As the GST-PTK2B constructs were difficult to produce and visualize with Coomassie blue staining (arrows), we checked the GST-PTK2B construct through detection of PTK2B by western blotting (middle panel). All results shown in panels ( a and b ) are representative of three independent experiments. ( c ) Western blotting analysis of Tau phosphorylation in different Fak conditions in the Drosophila eye. Actin is used as a loading control ( n =2-4). ( d ) Images and quantification of fly eyes co-expressing the 2N4R Tau isoform and a mCD8::GFP construct used as control or wild-type Fak or mutant Fak Y430F (scale bar 0.1 mm).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 Diet-induced HHcy in brain affects tau phosphorylation and pathology A. Brain cortex homogenates from h-tau mice receiving the low folate and B vitamins diet (DIET) or chow diet controls (CTR) from 4 to 12 months of age were assayed by HPLC for levels of Hcy, SAM, SAH, and the ratio SAM/SAH calculated (*p
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 Tau acetylation modulates tau phosphorylation at specific epitopes. (a-c ) Immunoblot analysis and quantification using the indicated tau antibodies for (a ) cells expressing WT tau-T40 and either an active form of CBP or a catalytically inactive form of CBP (CBP-LD), ( b ) cells co- expressing tau-T40 (WT, DeltaKK, 4KQ, or 4KR) and tau modifying enzymes, and ( c ) cells expressing tau-T40 (WT, DeltaKK, 2KQ, 4KQ, or 4KR) and treated with control (DMSO) or okadaic acid (OA), where indicated. Solid black arrows highlight the ~75 kDa phospho-tau species that is reduced upon acetylation. Statistical significance was assessed using a student t-test (****p < 0.0001). Cropped images from full size immunoblots are provided in panels a-c. Full-length immunoblots are presented in Supplementary Fig. S1 . ( d ) Immunofluorescence microscopy of primary cortical neurons expressing WT-tau-GFP (left) or 4KQ-tau-GFP (right) detecting phosphorylated tau (AT8). White arrows identify transfected neurons. Scale bar, 50 um.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Subcellular fractionation reveals location-specific Tau modification. ( a ) Cell lysates, cytosolic and nuclear fractions obtained from biological triplicates of C17.2 cells induced for human Tau expression for 24 hr are analysed by western blot with antibodies for Tau (Tau13), for the cytosolic GAPDH marker and for the nuclear histone 3 (H3) marker. Molecular weight markers are shown on the left. Full blots are presented in Supplementary Fig. 4 online. ( b ) Quantification is plotted as mean percent +- SD recovered in the two subcellular fractions. ( c ) Cytosolic and TCA-precipated nuclear fractions are analysed by western blot with antibodies for pan-Tau, against the indicated phosphosites or for dephosphorylated Ser 195 / 198 / 199 / 202 (biological triplicates). ( d ) Quantification of modified Tau normalized for the amount of total Tau detected in each sample. To facilitate the comparison between sites, each modified site is further normalized with the respective values measured in the cytosolic fraction. Values are mean +- SD, n = 3. 2way ANOVA and Bonferroni's multiple comparison test, *p < 0.05, ***p < 0.001.
